DDInter776 DDInter1676
Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isoprenaline
Formoterol {u} (Compound) resembles {v} (Compound) Fenoterol
Formoterol {u} may lead to a major life threatening interaction when taken with {v} Labetalol
Formoterol {u} (Compound) resembles {v} (Compound) Arbutamine
Formoterol {u} (Compound) treats {v} (Disease) chronic obstructive pulmonary disease
Formoterol {u} (Compound) binds {v} (Gene) ADRB1
Formoterol {u} (Compound) upregulates {v} (Gene) HMOX1
Formoterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Formoterol {u} (Compound) downregulates {v} (Gene) RPS4Y1
Formoterol {u} (Compound) causes {v} (Side Effect) Anxiety
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Formoterol (Compound) resembles Fenoterol (Compound)
Formoterol may lead to a major life threatening interaction when taken with Labetalol
Formoterol (Compound) resembles Arbutamine (Compound)
Formoterol (Compound) treats chronic obstructive pulmonary disease (Disease)
Formoterol (Compound) binds ADRB1 (Gene)
Formoterol (Compound) upregulates HMOX1 (Gene)
Formoterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Formoterol (Compound) downregulates RPS4Y1 (Gene)
Formoterol (Compound) causes Anxiety (Side Effect)